{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096204","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.049801+00:00","generated_at":"2026-05-31T09:44:46.579407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts","bullets":["Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.","Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).","ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.","ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.","Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096204","json":"https://secwatch.observer/filing/0000950170-24-096204.json","markdown":"https://secwatch.observer/filing/0000950170-24-096204.md","text":"https://secwatch.observer/filing/0000950170-24-096204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/0000950170-24-096204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/elvn-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:46.579407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}